The long journey of salicylates in ulcerative colitis: The past and the future

Journal of Crohn's and Colitis

Volumn 3, Issue 3, 2009, Pages 149-156

  Caprilli, Renzo ^a   Cesarini, Monica ^a   Angelucci, Erika ^a   Frieri, Giuseppe ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

MMX mesalazine; Salicylates; Ulcerative colitis

Indexed keywords

MESALAZINE; PLACEBO; SALAZOSULFAPYRIDINE; SALICYLIC ACID DERIVATIVE;

CANCER PREVENTION; CLINICAL TRIAL; COLORECTAL CANCER; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; PRIORITY JOURNAL; REVIEW; ULCERATIVE COLITIS;

EID: 67651087175     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2009.05.001     Document Type: Review

References (58)

1. Svartz N. Salazopyrin, a new sulfanilamide preparation. A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic effects in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparations. Acta Med Scand 110 (1942) 580-598
2. Svartz N. The treatment of 124 cases of ulcerative colitis with salazopyrin. Attempts at desensitization in cases of hypersensitiveness to sulphasalazine. Acta Med Scand Suppl. 206 (1948) 465
3. Bargen J.A. Treatment of ulcerative colitis with salicylazosulphapyridine. Med Clin North Am 33 (1949) 935
4. Truelove S.C., and Witts L.J. Cortisone in ulcerative colitis: final report of a therapeutic trial. Br Med J ii (1955) 1041-1048
5. Baron T.H., Connell A.M., Lennard-Jones J.E., et al. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet 1 (1962) 1094-1096
6. Misiewicz J.J., Lennard-Jones J.E., Connell A.M., et al. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet i (1965) 185-189
7. Dissanayake A.S., and Truelove S.C. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (salazopyrin). Gut 14 (1973) 923-926
8. Truelove S.C., and Witts L.J. Cortisone and corticotrophin in ulcerative colitis. Br Med J 1 (1959) 387-394
9. Lennard-Jones J.E., Misiewicz J.J., Connell A.M., et al. Prednisone as maintenance treatment for ulcerative colitis in remission. Lancet 1 (1965) 188-189
10. O'Morain C., Smethurst P., Dore C.J., et al. Reversible male infertility due to sulphasalazine: studies in man and rat. Gut 25 (1984) 1078-1084
11. Peppercorn M.A., and Goldman P. Distribution studies of salicylazosulphapyridine and its metabolites. Gastroenterology 63 (1973) 240-245
12. Das K.M., Eastwood M.A., McManus J.P.A., et al. The role of the colon in the metabolism of salicyl-azo-sulphapyridine. Scand J Gastroenterol 9 (1974) 137
13. Azad Khan A.H., Piris J., and Truelove S.C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 29 (1977) 892-895
14. Das K., and Eastwood M.A. Acetylation polymorphism of sulphapyridine in patients with ulcerative colitis and Crohn's disease. Clin Pharmacol Ther 18 (1975) 514
15. Schroder H., and Evans D.A. Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects. Gut 13 (1972) 278-284
16. Nielsen O.H., Verspaget H.W., and Elmegreen J. Inhibition of intestinal macrophage chemotaxis to leukotriene B4 by sulphasalazine, olsalazine and 5-aminosalicylic acid. Aliment Pharmacol Ther 2 (1988) 203-211
17. Lauritsen K., Laursen L.S., Bukhave K., et al. Effects of topical 5-aminosalycilic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in-vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 91 (1986) 837-844
18. Kaiser G.C., Yan F., and Polk D.B. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor KB activation in mouse colonocytes. Gastroenterology 116 (1999) 602-609
19. Rosseaux C., Lefebvre B., Dubuquoy L., et al. Intestinal anti-inflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 201 (2005) 1205-1215
20. Dubuquoy L., Rosseaux C., Thueru X., et al. PPARγ as a new therapeutic target in inflammatory bowel diseases. Gut 55 (2006) 1341-1349
21. Frieri G., Pimpo M.T., Palumbo G.C., et al. Rectal and colonic mesalazine concentration in ulcerative colitis: oral VS topical treatment. Aliment Pharmacol Ther 13 (1999) 1413-1417
22. Frieri G., Giacomelli R., Pimpo M.T., et al. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colon inflammation in patients with ulcerative colitis. Gut 47 (2000) 410-414
23. Hanauer S., Schwartz J., Robinson M., et al. Mesalazine capsules for treatment of active ulcerative colitis: results of a controlled trial. Am J Gastroenterol 88 (1993) 1188-1197
24. Safdi A.V., and Cohen R.D. Increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates. Aliment Pharmacol Ther 26 (2007) 1179-1186
25. De Vos M., Verdievel H., Schoonjans R., et al. Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations. Gut 33 (1992) 1338-1342
26. Campieri M., Lanfranchi G.A., Bazzocchi G., et al. Treatment of ulcerative colitis with high dose 5-aminosalicylic acid edema. Lancet 2 (1981) 270-271
27. Sutherland L.R., Martin F., Greers S., et al. 5-Aminosalicylic acid enemas in the treatment of distal ulcerative colitis, proctosigmoiditis and proctitis. Gastroenterology 92 (1987) 1894-1898
28. Barber G.B., Lee D.E., Antonioli D.A., et al. Refractory distal ulcerative colitis responsive to 5-aminosalicylate acid edema. Am J Gastroenterol 80 (1985) 612-614
29. Gionchetti P., Rizzello F., Venturi A., et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum 41 (1998) 93-97
30. Safdi M., DeMicco M., Sninsky C., et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 92 (1997) 1867-1871
31. Marshall J.K., and Irvine E.J. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 40 (1997) 775-781
32. Kam L., Cohen H., Dooley C., et al. A comparison of mesalamine suspension enema and oral sulphasalazine for treatment of active distal ulcerative colitis in adults. Am J Gastroenterol 91 (1996) 1338-1342
33. Ardizzone S., Doldo P., Ranzi T., et al. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis: a comparative trial vs Salofalk enema: the SAF-3 study group. Ital J Gastroenterol Hepatol 31 (1999) 677-684
34. Hanauer S. Dose-ranging study of mesalamine (Pentasa) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial: the U.S. ENTASA Enema Study Group. Inflamm Bowel Dis 4 (1998) 79-83
35. Frieri G., Pimpo M., Galletti B., et al. Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis. Dig Liver Dis 37 (Feb 2005) 92-96
36. Willoughby C.P., Aronson J.K., Agback H., et al. Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. Gut 23 (1982) 1081-1087
37. Selby W.S., Barr G.D., Ireland A., et al. Olsalazine in active ulcerative colitis. Br Med J 291 (1985) 1373-1375
38. Chan R.A., Pope D.J., Gilbert A.P., et al. Studies of two novel sulphasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci (1983) 609-615 (ns28)
39. Dew M.J., Hughes P.J., Harries A.D., et al. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. Br Med J ii (1982) 1012
40. Rasmussen S.N., Bondesen S., Hvidberg E.F., et al. 5-Aminosalycilic acid in slow release preparation: bioavailability, plasma level and excretion in humans. Gastroenterology 83 (1982) 1062-1070
41. Travis S., Stange E., Lèman N., et al. European evidence based consensus on the management of ulcerative colitis: current management. J Crohn's-Colitis 2 (2008) 24-62
42. Sutherland L., and MacDonald J.K. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis (review). The Cochrane Collaboration and published in The Cochrane Library (2008) Issue 2
43. Sutherland L., and MacDonald J.K. Oral5-aminosalicylic acid for maintenance of remission in ulcerative colitis (review). The Cochrane Collaboration and published in The Cochrane Library (2008) Issue 2
44. Odes S., Vardi H., Friger M., et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology 131 (2006) 719-728
45. Yen E.F., Kane S.V., and Ladabaum U. Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis. Am J Gastroenterol 103 (2008) 1-12
46. Brunner M., Assandri K., Kletter K., et al. Grastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment Pharmacol Ther 17 (2003) 395-402
47. Prantera C., Viscido A., Biancone L., et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMX. Inflamm Bowel Dis 11 (2005) 421-427
48. Kamm M.A., Sandborn W.J., Gassull M., et al. Once-daily, high-concentration MMx mesalamine in active ulcerative colitis. Gastroenterology 132 (2007) 66-75
49. Lichtenstein G.R., Kamm M.A., Boddu P., et al. Effects of once- or twice-daily MMx mesalamine (spd476) for the induction of remission of moderately active ulcerative colitis. Clin Gastroenterol Hepatol 5 (2007) 95-102
50. Moody G.A., Jayanthi V., Probert C.S., et al. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis. A retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 8 (1996) 1179-1183
51. Van Sta T.P., Cord T.R., Leufkens H.G., et al. 5-Aminosalycilate use and colon-rectal cancer risk in inflammatory bowel diseases: a large epidemiological study. Gut 54 (2005) 1573-1578
52. Bernstein C.N., Blanchard J.F., Metge C., et al. Does the use of 5-aminosalycilates in inflammatory bowel diseases prevent the development of colorectal cancer?. Am J Gastroenterol 98 (2003) 2784-2788
53. Terdiman J.P., Steinbuch M., Blumentals W.A., et al. 5-Aminosalycilic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis 13 (2007) 367-371
54. Velayos F.S., Terdiman J.P., and Walsh J.M. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metanalysis of observational studies. Am J Gastroenterol 100 (2005) 1354-1356
55. Hussan S.P. Inflammation and cancer: is AID aiding?. Gastroenterology 135 (2008) (736.737)
56. Endo J.M.H., Kow T., Nakase H., et al. Activation induced cytidine deaminase links between inflammation to colitis associated colo-rectal cancer. Gastroenterology 135 (2008) 889-898
57. Matula S., Croog V., Itzkowitz, et al. Chemioprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin Gastroenterol Hepatol 3 (2005) 1015-1021
58. Greten F.R., Eckmann L., Greten T.F., et al. IKK beta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004) 285-296